Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib. … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK).

  2. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.

  3. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

    Categories: Beta Blocking Agents, Non-Selective
  4. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". … The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation

  5. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    [L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. … Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids.

  6. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa treatment demonstrated good tolerability with no reports of inhibitor development in clinical studies [A31556]. … Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016.

  7. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    [A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]

  8. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also i...

    Mixtures: Phenaphen No 3 Cap, Phenaphen No 4 Cap
  9. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

    Synonyms: N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine, N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
  10. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.